Cancer
January 19, 2023
One of the intriguing phenomena with the R&D of anticancer drugs is that many non-anticancer commercial drugs on the market are excellent anticancer candidates and exhibit the potential to outperform existing anticancer drugs, such as those in the categories of pancreatic cancer and NSCLC. Another good opportunity is that professionals can extend clinical practices of many anticancer drugs to other therapeutic fields, including oncology and others.
Quite a few investigational anticancer drugs in the early phases of clinical trials seldom fit their correct roles. This issue is formed mainly by two reasons: (a) unqualified candidates and (b) wrong targets or target zones, including improper solubilities. A current solution is to set up several clinical trials for testing errors of a single candidate. Sooner or later, patients, pharm companies, and taxpayers must pay bills for the unsuccessful efforts. These improper practices consume precious resources for vague goals, and hence there is plenty of space for improvements in the long run.
Fundamental changes are necessary to provide better medications to patients as part of the cornerstones. Here are some examples:
• Replacement of anticancer drugs low in performance by optimized candidates regarding
their capabilities of inhibiting tumor growth and anchoring on target zones.
• Enlargement of the coverage of target zones where tumors exist and grow through the
drugs in the same family with different solubilities.
• Utilization of the drugs with multiple relevant target zones on the path of metastasis of
tumor cells as a prevention and treatment approach.
• The clarification and then the classification of present commercial anticancer drugs,
based on their fundamental therapeutic mechanisms with clinical practices of many years.
• Development of new diagnostic technologies centered on lessons learned from treatments
of cancers with patients for better clinical practices in the coming future.
Despite significant progress in this field, curing cancers or making them manageable is still one of the biggest challenges that humans have been facing. It is time to move forward to a new arena by employing the solid foundation paved by scientists and medical professionals worldwide over decades.